Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.06 USD | -9.42% | -3.81% | -32.59% |
Sales 2024 * | 22Cr 1.87TCr | Sales 2025 * | 32Cr 2.67TCr | Capitalization | 51Cr 4.24TCr |
---|---|---|---|---|---|
Net income 2024 * | -28Cr -2.36TCr | Net income 2025 * | -15Cr -1.23TCr | EV / Sales 2024 * | 2.76 x |
Net Debt 2024 * | 11Cr 930.03Cr | Net Debt 2025 * | 12Cr 985.99Cr | EV / Sales 2025 * | 1.96 x |
P/E ratio 2024 * |
-1.98
x | P/E ratio 2025 * |
-3.96
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.26% |
Latest transcript on Travere Therapeutics, Inc.
1 day | -9.42% | ||
1 week | -3.81% | ||
Current month | +9.58% | ||
1 month | +1.17% | ||
3 months | -26.81% | ||
6 months | +3.59% | ||
Current year | -32.59% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 04/19/04 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 01/14/01 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 04/22/04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 31/15/31 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 08/14/08 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 08/20/08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - | |
0.06% | 1,487 M€ | +9.17% | - |
Date | Price | Change | Volume |
---|---|---|---|
18/24/18 | 6.06 | -9.42% | 1 321 520 |
16/24/16 | 6.69 | -1.62% | 930,732 |
15/24/15 | 6.8 | +1.49% | 1,027,766 |
14/24/14 | 6.7 | +5.68% | 1,116,588 |
13/24/13 | 6.34 | +0.63% | 792,503 |
Delayed Quote Nasdaq, May 18, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.59% | 51Cr | |
+9.42% | 11TCr | |
+11.84% | 10TCr | |
-14.15% | 2.24TCr | |
-1.05% | 2.23TCr | |
-5.29% | 1.91TCr | |
-38.29% | 1.8TCr | |
-4.16% | 1.79TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.25TCr |
- Stock Market
- Equities
- TVTX Stock